1. Introduction {#s0005}
===============

Advances in the treatment of HIV infection have dramatically reduced AIDS mortality and improved the quality of life of many people living with HIV ([@bb0005]). The initiation of ART results in a rapid drop in plasma viral load and in a substantial reduction in the number of cells carrying proviral DNA in both blood and tissues ([@bb0010], [@bb0015]). However, ART alone does not eradicate HIV. The virus persists in long-lived latently infected CD4 + T cells that can produce infectious particles following T cell stimulation ([@bb0020], [@bb0025], [@bb0030]). The magnitude of the latent reservoir is highly variable among virally suppressed individuals and is influenced by a variety of factors including the nadir CD4 + T cell count ([@bb0035]), the CD4/CD8 ratio ([@bb0040]), the time between infection and initiation of ART ([@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070]) and, to a lesser extent, the duration of therapy ([@bb0075]). Because strategies targeting this latent reservoir are now being tested in clinical trials, well-validated high-throughput assays that quantify this reservoir are urgently needed to evaluate the effectiveness of these interventions.

Several assays have been developed to measure HIV persistence in virally suppressed subjects who have received ART for years ([@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125], [@bb0130], [@bb0135]). The quantitative viral outgrowth assay (Q-VOA) performed on purified resting CD4 + T cells isolated from patients on suppressive ART is considered the gold standard method to measure the minimum frequency of latently infected cells with replication competent virus ([@bb0020], [@bb0090], [@bb0140]). However, this assay is time-consuming, labour intensive, expensive and requires large volumes of blood (120--180 ml). Recently, a more rapid and simplified version of Q-VOA has been described ([@bb0145]), but this novel assay still requires large number of cells and has not been adapted to a large scale clinical trial. In addition, Ho et al. identified intact proviruses from p24 negative wells of the virus outgrowth assay, which raises the possibility that the Q-VOA underestimates the size of the *in vivo* latent reservoir ([@bb0150]). This could be attributed to the fact that HIV reactivation in this system is inherently stochastic, as recently proposed ([@bb0155]).

An alternative to the Q-VOA is the use of PCR-based methods that measure the frequency of cells harbouring HIV genomes (either total or integrated HIV DNA) ([@bb0095], [@bb0105], [@bb0120], [@bb0130], [@bb0135]). Although these methods can be used in large cohort studies, they are often criticized, as a large number of the viral genomes quantified by these assays are not replication-competent. Indeed, total HIV DNA in PBMCs and resting CD4 + T cells generally yields infected cell frequencies that are 2--3 logs higher than the Q-VOA, reflecting the high occurrence of defective and non-inducible viral genomes ([@bb0115]). Notwithstanding this limitation, measuring viral DNA, and particularly integrated HIV DNA, has provided crucial information that have contributed to the understanding of the mechanisms of HIV persistence during ART ([@bb0070], [@bb0160], [@bb0165], [@bb0170], [@bb0175]). Levels of HIV DNA predict viral rebound after structured treatment interruption ([@bb0180], [@bb0185]) and integrated HIV DNA is the only assay that appears to correlate with Q-VOA ([@bb0115]) although it is likely that frequencies of cells bearing HIV DNA greatly overestimates the size of the inducible latent HIV reservoir ([@bb0115]). These studies thus emphasize the need to develop novel assays that would measure the size of the latent and inducible HIV reservoir in a simple, reproducible and cost-effective manner.

An ideal assay would measure the frequency of latently infected CD4 + T cells without relying on the amplification of viral replication, which is difficult to control and requires at least a week of cell culture. Measuring the production of viral particles in culture supernatants of stimulated cells is attractive ([@bb0190]), but would require ultracentrifugation and RNA extraction steps that are not desirable for a clinical trial scalable assay. Cell associated RNA is an alternative virological marker that can be easily measured in a limiting dilution assay.

Low amounts of cell-associated unspliced HIV RNA are frequently detected in PBMCs from virally suppressed subjects on ART ([@bb0080], [@bb0195], [@bb0200], [@bb0205], [@bb0210]), as well as in latently infected CD4 + T cells that do not produce HIV particles ([@bb0215], [@bb0220], [@bb0225]), and therefore, cannot be used as a surrogate for viral release ([@bb0190], [@bb0230]). In contrast, *tat*/*rev* multiply spliced RNA (msRNA) reflects the ability of a cell to produce virus ([@bb0080], [@bb0110], [@bb0210], [@bb0200], [@bb0215], [@bb0205], [@bb0220], [@bb0225], [@bb0235], [@bb0240]). Of note, recent data indicate that tat positive feedback alone may be sufficient in reversing latency, independent of cellular activation ([@bb0245]), suggesting that *tat* transcripts may be used as a surrogate for productive infection. This is consistent with the fact that direct addition of tat activates viral expression in resting CD4 + T cells without requiring cellular activation ([@bb0250], [@bb0255]). In addition, many defective HIV genomes have deletions that encompass the *tat* and *rev* genes ([@bb0150]), indicating that transcripts from these genes are very unlikely to be generated in cells harbouring defective proviruses. This provides a rationale for the development of a sensitive assay that can detect *tat*/*rev* msRNA upon maximal stimulation.

Here, we report the development of TILDA, a novel assay that measures the frequency of cells harbouring viral genomes that produce *tat*/*rev* multiply-spliced HIV RNA upon maximal stimulation. By combining ultrasensitive detection of msRNA and maximal activation of CD4 + T cells in a limiting dilution format, this method allowed us to measure the frequency of cells capable of being induced to produce HIV RNA transcripts. Significantly, this assay has potential for application in larger clinical trials and cohort studies as it requires only 10 ml of blood, is robust, sensitive, covers a wide dynamic range of reservoir size and can be completed in two days.

2. Methods {#s0010}
==========

2.1. Participants and Samples {#s0025}
-----------------------------

Samples from 20 subjects on stably suppressive ART and from 13 viremic subjects not receiving ART at the time of sampling were used in this study. None of the participants under ART experienced any detectable plasma viremia at the time of study, as assessed by viral load measurement using the Ampliprep/Cobas Taqman HIV-1 Test v 2.0 (Roche), with a detection limit of 20 copies/ml of plasma. These subjects had an undetectable viral load for an average of 6 years (range 3--17 years). All participants underwent leukapheresis to collect large numbers of PBMCs. Subjects characteristics are summarized in [Table 1](#t0005){ref-type="table"}.

Data presented in [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"} were generated by analysing samples obtained from individuals who participated in a previous study aimed at comparing different assays to measure HIV persistence ([@bb0115]). Briefly, this study enrolled 30 subjects from two well-established cohorts at the University of California San Francisco (UCSF). Samples from 27 of these participants were used for the present study (17 from the SCOPE cohort and 10 from the OPTIONS cohort). All of the 27 subjects had at least 36 months of continuous ART at study entry with no regimen changes in the preceding 24 weeks and maintenance of plasma HIV RNA levels below the limit of detection of conventional assays for at least 36 months (intermittent isolated episodes of detectable low-level viremia were allowed). Primary or recent HIV infection was defined if one or several of these 3 criteria were met: ([@bb0005]) repeated plasma HIV RNA \> 5000 copies/ml combined with a negative or indeterminate HIV antibody test; ([@bb0010]) seroconversion within 6 months of a documented negative HIV antibody test; ([@bb0015]) a history compatible with primary HIV infection (including no prior positive HIV antibody tests) and laboratory testing consistent with recent infection on the "detuned" antibody EIA. Characteristics of these participants can be found in [@bb0115].

This study was approved by the Martin Health System Institutional review board and by the UCSF Committee on Human Research. All study subjects provided written informed consent prior to participation in the study.

2.2. Isolation of CD4 T cells {#s0030}
-----------------------------

PBMCs were isolated from the leukapheresis product by Ficoll Hypaque density gradient centrifugation and cryopreserved in liquid nitrogen. Upon thawing of the PBMCs, total CD4 + T cells were isolated by negative magnetic selection (Stemcell technologies). The purity of enriched CD4 + T cells was generally greater than 95%, as assessed by flow cytometry.

2.3. TILDA {#s0035}
----------

Enriched CD4 + T cells were resuspended at 2 × 10^6^ cells/ml in RPMI + 10% foetal bovine serum and rested for 3--5 h at 37 °C, 5% CO~2~. In some experiments, antiretroviral drugs were added to the culture medium (200 nM raltegravir, 100 nM efavirenz and 180 nM AZT). CD4 + T cells were stimulated for 12 h with 100 ng/ml PMA and 1 μg/ml ionomycin (both from Sigma). The duration of 12 h was based on kinetic experiments demonstrating maximal production of *tat*/*rev* RNA and preserved cell viability at this time point (not shown). After stimulation, cells were washed in RPMI, counted and serially diluted to 18 × 10^6^ cells/ml, 9 × 10^6^ cells/ml, 3 × 10^6^ cells/ml and 1 × 10^6^ cells/ml in culture medium. 1 μl of the cell suspension from each serial dilution was distributed in 22 to 24 wells of a 96 well plate containing 5 μl of 2 × reaction buffer from the SuperScript III Platinum One-Step qRT-PCR Kit (Life Technologies) corresponding to 18,000, 9000, 3000 and 1000 cells per well. Different cell numbers were used for samples obtained from viremic, untreated HIV-infected individuals (9000; 3000; 1000 and 333 cells per well). In some experiments, a fraction of the isolated CD4 + T cells were immediately distributed in limiting dilutions after thawing to quantify the frequency of cells that spontaneously produce HIV msRNA (no stimulation). Similar frequencies of positive cells were measured by TILDA whether the cells were distributed immediately after thawing or after 12 h of resting (not shown). Pre-amplification was carried out by adding 5 μl of a PCR mix containing 0.2 μl Superscript III Platinum Taq (Life Technologies), 0.1 μl RNase inhibitor (Life Technologies), 0.125 μl of each primer (tat1.4 and rev both at 20 μM), 2.2 μl Tris--EDTA (TE) buffer and 2.25 μl H~2~O to each well (final reaction volume = 11 μl). The sequences of the oligonucleotides were slightly adapted from [@bb0110]: tat1.4: 5′-TGG CAG GAA GAA GCG GAG A-3′; rev: 5′-GGA TCT GTC TCT GTC TCT CTC TCC ACC-3′. Pre-amplification was carried out using the following steps: reverse transcription at 50 °C for 15 min, denaturation at 95 °C for 2 min, 24 cycles of amplification (95 °C 15 s, 60 °C 4 min) on a C1000 PCR instrument (Biorad). At the end of the pre-amplification, 40 μl of TE buffer was added to each well and 1 μl of the diluted PCR products was used as template for the *tat*/*rev* real-time PCR reaction. This reaction was performed by adding 5 μl of the Lightcycler Probe Master buffer (Roche Applied Sciences), 0.2 μl of each primer (tat2 and rev, both at 20 μM), 0.2 μl of the probe HIV FamZen at 5 μM and 3.4 μl H~2~O to each well (final reaction volume = 10 μl). Sequence of tat2 and the HIV probe were also adapted from ([@bb0110]): tat2: 5′- ACA GTC AGA CTC ATC AAG TTT CTC TAT CAA AGC A -3′. Probe HIV: 5′-/56-FAM/TTC CTT CGG /ZEN/GCC TGT CGG GTC CC/3IABkFQ/-3‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬′. All primers and probes were synthesized by IDT. The real-time PCR reaction was carried out in a Light Cycler 480 II (Roche Life Science) using the following programme: Preincubation 95 °C for 10 min, 45 cycles of 95 °C 10 s, 60 °C 30 s, 72 °C 1 s and a cooling step at 40 °C fro 30 s. Positive wells at each dilution were counted and the maximum likelihood method was used to calculate the frequency of cells with inducible HIV msRNA (<http://bioinf.wehi.edu.au/software/elda>).

2.4. Statistical Analysis {#s0040}
-------------------------

Baseline and induced TILDA values were compared using the Wilcoxon matched-pairs signed rank test. For correlations between values obtained with different assays, normality of the log transformed virologic data was tested with the D\'Agostino--Pearson test. With the exception of total HIV DNA in resting CD4 + T cells and residual viremia by single copy assay, all virologic data met the normality test and correlations were performed on log-transformed values using the Pearson test. When the data did not meet the normality test, the Spearman test was used. When the result of an assay was negative (below the limit of detection), an imputed value representing the lower of the limit of detection was used in the calculation of the Pearson correlation coefficient. In the case of the single-copy assay for HIV-1 RNA in plasma, for which one-third of the measurements was below the limit of detection (0.2 copies/ml), a low imputed value of 0.1 was used to calculate the Spearman rank correlation coefficient. Virologic data obtained from subjects who started ART during the early and chronic phases of infection were compared using a two-tailed Mann--Whitney test. Data analysis was done using Microsoft Excel and Prism 6.0.

3. Results {#s0015}
==========

3.1. Principle of TILDA {#s0045}
-----------------------

We sought to develop an assay that detects *tat*/*rev* msRNA (adapted from [@bb0110]) in maximally activated CD4 + T cells, using a limiting dilution format, postulating that this method will allow us to measure the frequency of cells harbouring inducible viruses. We chose to activate the cells with phorbol 12-myristate 13-acetate (PMA), which has been shown to induce a rapid onset of increased transcription from the HIV LTR in latently infected cell lines ([@bb0260]), induces higher levels of viral production than PHA ([@bb0265]) and activates rare T cell subsets ([@bb0270]). Ionomycin, a calcium ionophore, is added to trigger calcium release, a requirement for N-FAT signalling. PMA ionomycin has been shown to induce high levels of viral production in several primary cell models of HIV latency ([@bb0275]) as well as in CD4 + T cells from virally suppressed individuals ([@bb0280], [@bb0285]). After stimulation, cells are distributed in 24 replicate wells in a 96 well plate and a nested PCR amplifying *tat*/*rev* transcripts is directly performed without RNA extraction ([Fig. 1](#f0005){ref-type="fig"}A). Using the maximum likelihood method, the frequency of cells producing msRNA is calculated. TILDA can also be used to measure the frequency of CD4 + T cells that spontaneously produce msRNA *ex vivo* by omitting the stimulation step.

3.2. TILDA is Specific, Sensitive and Reproducible {#s0050}
--------------------------------------------------

We first evaluated the sensitivity and specificity of TILDA. We infected activated CD4 + T cells with an infectious HIV clone containing a GFP reporter (NL4-3 nef IRES GFP). Two days postinfection, we sorted GFP + and GFP- cells and used our assay to detect *tat*/*rev* msRNA in wells containing single cells ([Fig. S1A](#ec0005){ref-type="supplementary-material"}). Among 48 well containing GFP + cells, 42 were positive for HIV DNA and GAPDH (88%). 79% (33/42) of these were positive by TILDA. In contrast, none of the 48 wells containing GFP negative cells were positive for msRNA, in spite of a significant fraction of these well containing HIV DNA (42/48, 88%). These results suggested that the presence of msRNA is a specific surrogate for the production of viral proteins, at least in this *in vitro* system of HIV infection.

Using samples obtained from 4 virally suppressed subjects, we determined the robustness of TILDA *i*.*e*., intra- and inter-assay coefficients of variation; we measured the frequency of CD4 + T cells producing *tat*/*rev* msRNA upon stimulation with PMA/ionomycin in duplicate plates or in up to 4 independent experiments performed by different operators. The intra and inter-assay coefficients of variation of TILDA were 0.15 and 0.21, respectively ([Fig. S1B](#ec0005){ref-type="supplementary-material"}) confirming the robustness of this assay. The theoretical dynamic range of TILDA is \> 3logs~10~ with minimal and maximal detectable values of 1.4 and 3185 cells/10^6^ CD4 + T cells, respectively. Of note, all the experimental values determined in this study ranged over 3 logs, a dynamic range of TILDA that is large enough to efficiently measure low frequency of infected cells as is the case in the vast majority of virally suppressed individuals ([Fig. S1C](#ec0005){ref-type="supplementary-material"}). Importantly, the limit of detection of TILDA indicated above (1.4 cells/10^6^ CD4 + T cells) is based on the number of cells plated in a typical experiment (744,000 cells corresponding to 24 × 18,000 + 24 × 9000 + 24 × 3000 + 24 × 1000) and can further be lowered by increasing the number of cells assayed in multiple plates.

3.3. TILDA Measures the Frequency of CD4 + T cells With Inducible msRNA in Virally Suppressed Individuals on ART {#s0055}
----------------------------------------------------------------------------------------------------------------

We used TILDA to measure the frequency of CD4 + T cells producing *tat*/*rev* msRNA in samples from 20 virally suppressed subjects on suppressive ART for a median time of 6 years ([Table 1](#t0005){ref-type="table"}). As expected, the frequency of cells spontaneously producing msRNA was low (median = 2.7 cells/10^6^ CD4 + T cells, [Fig. 1](#f0005){ref-type="fig"}B), and even below the limit of detection in 5 out of 19 samples (26%). CD4 + T cells producing tat/rev RNA were detected in all samples upon stimulation, with a median frequency of cells producing msRNA of 50 cells/10^6^ CD4 + T cells (p \< 0.0001). By subtracting the baseline from the induced values, we calculated the frequency of cells carrying inducible HIV. We estimated that only 7.3% of CD4 + T cells with the ability to generate msRNA produced these transcripts spontaneously, whereas the majority (92.7%) of cells were devoid of msRNA *ex vivo* but produced them upon stimulation with PMA/Ionmycin ([Fig. 1](#f0005){ref-type="fig"}C). These results are in line with previous reports demonstrating that the majority of infected cells in individuals on suppressive ART, harbour latent HIV and do not spontaneously produce viral particles ([@bb0140], [@bb0290], [@bb0295]). These results demonstrated that TILDA can be used to measure the frequency of CD4 + T cells that have the ability to produce HIV msRNA upon stimulation in virally suppressed subjects.

3.4. TILDA Values Correlate With Several Assays Measuring HIV Persistence During ART {#s0060}
------------------------------------------------------------------------------------

We next compared the frequency of latently infected CD4 + T cells measured by TILDA with values obtained from a variety of well-established assays ([@bb0090], [@bb0095], [@bb0100], [@bb0130], [@bb0300]). For this purpose, we used samples that were originally used to compare Q-VOA with several PCR-based assays ([Table 2](#t0010){ref-type="table"}) ([@bb0115]). In these samples obtained from 27 participants of the SCOPE and Options studies, we found that the median frequency of latently infected CD4 + T cells measured by TILDA was 24 cells/10^6^ CD4 + T cells (range 1.4--101 cells/million), which was 48 times higher than frequencies measured by Q-VOA (median = 0.5, range 0.03--16 cells/10^6^ CD4 + T cells), and 6--27 times lower than frequencies of infected cells measured by PCR-based assays ([Table 2](#t0010){ref-type="table"}).

We then determined correlations between the values obtained by TILDA and the other assays used to measure the size of the HIV reservoir using samples from the same group of subjects. TILDA values were positively correlated with the frequency of PBMCs harbouring total HIV DNA (r = 0.38, p = 0.05, [Fig. 2](#f0010){ref-type="fig"}A) and integrated HIV DNA (r = 0.68, p = 0.002, [Fig. 2](#f0010){ref-type="fig"}B) as well as with the frequency of rectal CD4 + T cells harbouring total HIV DNA (r = 0.70, p = 0.002, [Fig. 2](#f0010){ref-type="fig"}C). Although TILDA values tended to correlate with the frequencies of resting CD4 + T cells harbouring total and integrated HIV DNA, these correlations did not reach statistical significance (ρ = 0.48, p = 0.083 and r = 0.47, p = 0.076, respectively, [Fig. 2](#f0010){ref-type="fig"}D and E). Of note, the number of samples in which total and integrated HIV DNA were measured in resting CD4 + T cells was limited (n = 14 and 15, respectively, [Table 2](#t0010){ref-type="table"}), which curtailed our capacity to detect significant associations between TILDA and these two assays. TILDA values did not correlate significantly with residual viremia, although a trend for a negative association was noted (ρ = − 0.35, p = 0.070, [Fig. 2](#f0010){ref-type="fig"}F). The frequency of resting CD4 + T cells harbouring replication competent HIV measured by Q-VOA tended to correlate with TILDA, but this was not statistically significant in this relatively small population of virally suppressed individuals (r = 0.33, p = 0.095, [Fig. 2](#f0010){ref-type="fig"}G); this may be attributed to the fact that Q-VOA uses resting CD4 + T cells, whereas TILDA is performed on total CD4 + T cells that include homeostatically proliferating cells. Altogether, these results demonstrate that TILDA can be efficiently used to measure the frequency of CD4 + T cells producing msRNA upon stimulation, a frequency that correlates with several assays that measure HIV persistence.

3.5. Initiation of ART During Early HIV Infection Leads to a Restricted Size of the Reservoir During Therapy Measured by TILDA {#s0065}
------------------------------------------------------------------------------------------------------------------------------

We measured the frequency of infected cells with inducible msRNA in virally suppressed subjects who initiated ART during recent (n = 10) or chronic (n = 17) infection ([Fig. 3](#f0015){ref-type="fig"}). Using TILDA, we observed that the size of the reservoir was significantly smaller in subjects who started ART during recent infection (\< 6 months) when compared to those who initiated therapy at a later stage of the disease (median frequencies of 11 and 29 cells/10^6^ CD4 + T cells in early and chronic infection respectively, p = 0.011). This was in line with the results form previous studies ([@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0305], [@bb0115]), in which a lower frequency of reservoir cells was measured in subjects who started ART early when using Q-VOA, integrated HIV DNA in PBMCs and total HIV DNA in resting CD4 + T cells.

3.6. TILDA Reveals the Existence of a Large Pool of Latently Infected CD4 + T cells in HIV-infected Individuals who do not Receive ART {#s0070}
--------------------------------------------------------------------------------------------------------------------------------------

Our results confirm that the latent HIV reservoir is established early in infection ([@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070]). However, the relative proportion of productively and latently infected CD4 + T cells during untreated HIV infection is not known. As TILDA can measure the frequency of cells spontaneously producing msRNA as well as the frequency of cells that has the ability to do so upon maximal stimulation ([Fig. 1](#f0005){ref-type="fig"}), we used our assay to measure both frequencies in CD4 + T cells obtained from HIV-infected individuals who did not receive ART ([Table 1](#t0005){ref-type="table"}). CD4 + T cells containing *tat*/*rev* transcripts at baseline were readily detected in all samples from viremic individuals ([Fig. 4](#f0020){ref-type="fig"}A). Overnight stimulation with PMA/ionomycin led to a significant increase in the frequency of CD4 + T cells producing msRNA (median fold increase of 7.4 in the frequency of cells with HIV msRNA, p = 0.0005). The frequency of cells spontaneously producing these transcripts was strongly correlated with plasma viral load (r = 0.81, p = 0.0014, [Fig. 4](#f0020){ref-type="fig"}B). Our calculations indicate that only a minor fraction (18.6%) of CD4 + T cells with inducible HIV genomes were spontaneously producing *tat*/*rev* transcripts *in vivo* ([Fig. 4](#f0020){ref-type="fig"}C), whereas the majority of infected cells (81.4%) were latently infected and produced msRNA only upon stimulation. Therefore, similar to virally suppressed subjects, ART-naïve individuals harbour a large pool of CD4 + T cells in which msRNA can be induced upon stimulation ([Fig. 4](#f0020){ref-type="fig"}D). The frequency of latently infected CD4 + T cells in untreated HIV-infected individuals was positively correlated with the duration of HIV infection (r = 0.71, p = 0.0097, [Fig. 4](#f0020){ref-type="fig"}E), suggesting that the size of the latent and inducible reservoir gradually increases in untreated viremic subjects, a consequence of continuous seeding of the HIV reservoir.

Non-integrated HIV DNA molecules are present at high frequencies in CD4 + T cells isolated from viremic HIV-infected individuals ([@bb0070], [@bb0310]). Integration and transcription of these linear genomes may account for the increase in the frequency of CD4 + T cells producing msRNA we observed upon stimulation with PMA/ionomycin. To test for this possibility, we repeated these experiments in the presence of antiretroviral drugs, including the integrase inhibitor raltegravir. We observed that the addition of raltegravir to the culture medium had no impact on the increase in the frequency of cells producing msRNA upon stimulation. This indicated that the increase in the frequency of CD4 + T cells producing msRNA is attributable to viral genomes that were already integrated before stimulation, demonstrating that post-integration latency can be detected and measured in viremic HIV-infected subjects who do not receive ART.

4. Discussion {#s0020}
=============

The definitive test of an HIV cure will require the interruption of ART. It is necessary, however, to measure the impact of eradication strategies on the size of the viral reservoir even as therapy is continued if clinical trials are to proceed in an efficient and ethical manner ([@bb0315]). A large number of assays have been developed to measure the frequency of infected cells that persist in virally suppressed subjects who have received ART for years ([@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125], [@bb0130], [@bb0135]). Each assay measures different parameters (replication competent HIV, total and integrated HIV DNA, cell associated HIV RNA, viral particles) in different cells types (PBMCs, CD4 + T cells and resting CD4 + T cells). These assays provide a frequency of persistently infected cells that can range over 2 logs in the same individual ([@bb0115]). For example, the size of the reservoir is likely to be overestimated by PCR assays, which can include a large proportion of defective viruses. On the other hand, the reservoir is likely to be underestimated by the Q-VOA assay as it does not capture all cells carrying replication competent HIV ([@bb0150]). This prompted us to develop an assay that would not measure the background attributed to defective genomes and that would not rely on the amplification of viral replication, a step that requires at least seven days of cell culture. Unlike cells that produce unspliced and often short HIV gag RNA ([@bb0320]), infected cells that are actively producing msRNA (particularly *tat*/*rev* transcripts) can produce virions ([@bb0080], [@bb0110], [@bb0210], [@bb0205], [@bb0215], [@bb0220], [@bb0225], [@bb0235]). This well-characterized process suggests that quantification of *tat*/*rev* msRNA may prove to be a sensitive and reproducible manner to estimate the frequency of cells harbouring transcriptionally silent -- nonetheless inducible -- viruses after maximal stimulation.

TILDA does not rely on the amplification of viral replication and offers similar advantages of the DNA PCR assays with regard to simplicity and small blood volume requirement. It does not require RNA extraction and 96-well plates with serially diluted cells can be stored at − 80 °C for future quantification in batch analyses, making TILDA well-suited for longitudinal clinical studies. Therefore, TILDA has a number of characteristics that make it attractive for clinical trials, particularly in paediatric studies in which the number of cells that can be obtained are often limited. In addition, TILDA could be used to measure the frequency of infection in rare population of cells, which may facilitate the measurement of the HIV reservoir in tissues.

Using TILDA, we found the median frequency of latently infected CD4 + T cells during ART to be 24 cells/million, which is 48 times more than the frequency measured by the quantitative viral outgrowth assay. Ho et al. recently reported that the median frequency of intact noninduced proviruses is around 60-fold higher than the frequency of induced proviruses detected in Q-VOA ([@bb0150]). Therefore, TILDA may provide an accurate estimate of the size of the latent HIV reservoir, although the precise fraction of the replication competent latent and inducible HIV reservoir captured by TILDA will require further studies. Similarly, evaluating the ability of TILDA to predict viral rebound upon ART interruption will necessitate the development of well-powered clinical trials and cannot be inferred from our current observations.

TILDA correlated with several PCR-based assays that measure the size of the latent reservoir, including the quantification of total and integrated HIV DNA in PBMCs. TILDA tended to correlate with the size of the reservoir measured by Q-VOA, but this was not statistically significant. Our data are consistent with a lack of strong correlation between these two measures although the lack of statistical significance may reflect, in part, the sample size. The lack of correlation between the two assays may also result from the fact that Q-VOA is performed on purified resting CD4 + T cells, whereas total CD4 + T cells are used for TILDA determinations. Total CD4 + T cells include cells undergoing homeostatic proliferation which express some activation markers and are not captured in the Q-VOA assay. Ho et al. reported that Q-VOA does not correlate strongly with the frequency of cells harbouring intact non-induced proviruses ([@bb0150]), suggesting that it may not provide an accurate estimate of the frequency of latently infected CD4 + T cells. Whether TILDA could provide a better estimate of the size of the replication competent reservoir remains to be determined by using full-length sequencing approaches, similar to the ones used by Ho et al. and others ([@bb0150], [@bb0325]).

Using TILDA, we observed that early initiation of ART leads to a reduced size of the viral reservoir after years of viral suppression. This is in line with several reports that have clearly demonstrated the benefit of early therapy on the size of the latent HIV reservoir ([@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0305], [@bb0070]). In addition, we demonstrated that before the initiation of ART, the latent HIV reservoir already represents a substantial fraction of all infected CD4 + T cells and that the size of the reservoir increases with time during untreated HIV infection. This observation further argues for early ART intervention to prevent the establishment and continuous seeding of an increasingly large pool of latently infected CD4 + T cells.

Although TILDA constitutes an attractive alternative to other methods to measure the size of the latent HIV reservoir, there are potential limitations associated with the use of our assay. First, although all cells that are releasing viral particles are producing *tat*/*rev* msRNA, the opposite may not be necessarily true. We cannot exclude the possibility that some cells that generate a positive signal in TILDA do not produce virions. Indeed, very low levels of nuclear msRNA can be detected in resting CD4 + T cells using ultrasensitive approaches ([@bb0320], [@bb0250]). Therefore, TILDA is likely to overestimate the size of the latent and replication competent reservoir. Notwithstanding this limitation, TILDA is more likely to capture the functional reservoir than other existing PCR-based assays: TILDA positive events result from the transcription of integrated HIV genomes that have an intact LTR (to ensure transcription) and that are not deleted in the two most commonly deleted regions identified in defective genomes namely *tat* and *rev* ([@bb0330]). Of note, TILDA measures frequencies of latently infected CD4 + T cells close to those predicted to harbour replication competent virus in the study by [@bb0150]. Another potential caveat of TILDA is the fact that it relies on the amplification of a highly variable region of the HIV genome, suggesting that the primers and probes used in our assay may not recognize all viral quasispecies. We anticipate that the use of TILDA on HIV clades other than B will require further validation and optimization.

In conclusion, we report the development and validation of TILDA, a novel assay to measure the size of the latent reservoir that is quantitative, sensitive, robust and requires only 10 ml of blood. Moreover, results can be generated in two days. As such, TILDA may represent an alternative to existing assays used to evaluate the efficacy of therapeutic strategies aimed at reducing the size of the latent HIV reservoir.

The following is the supplementary data related to this article.Supplementary Fig. 1Performance of TILDA. (A) Activated CD4 + T cells were infected with HIV pNL4.3-GFP. GFP + and GFP- cells were sorted and *tat*/*rev* RNA were detected in single cells. The amplifications curves obtained from 24 GFP + and 24 GFP- cells are shown. (B) TILDA measurements were performed in duplicate in the same experiments or 3 to 4 times in independent experiments to calculate the intra and inter-assay coefficients of variation of the assay. Horizontal bars show means and standard deviations. (C) Dynamic range of TILDA: All TILDA values determined in samples obtained from virally suppressed subjects participating in the present study are represented. Unstimulated (spontaneous) and stimulated TILDA values are represented by grey and black circles, respectively. Horizontal dotted lines show the lower and upper limits of detection of the assay.
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![TILDA can be used to measure the frequency of persistently infected cells in blood samples from virally suppressed subjects. (A) Principle of TILDA: PBMCs were isolated from 10--20 ml of blood and CD4 + T cells were enriched by negative magnetic selection. CD4 + T cells were precisely counted and directly distributed in a 96 well plate or stimulated for 12 h with PMA/ionomycin. *Tat*/*rev* msRNA were quantified by an ultrasensitive nested RT-PCR and the frequency of cells with inducible msRNA was determined using the maximum likelihood method. (B) Frequency of CD4 + T cells producing msRNA spontaneously (baseline, n = 19) or after 12 h of stimulation (induced, n = 20) in samples obtained from virally suppressed subjects. Horizontal bars indicate median values. For samples in which no positive cells were detected at baseline, the limit of detection (based on cell input) is plotted and represented as a crossed circle. P value was obtained from the Wilcoxon matched-pairs signed rank test. (C) Proportion of CD4 + T cells that produce msRNA spontaneously or after stimulation in virally suppressed subjects on ART. Only samples with detectable values at baseline (panel B) are represented.](gr1){#f0005}

![TILDA correlates with several measures of HIV persistence. (A) Correlation between TILDA and the droplet digital PCR assay for HIV DNA in PBMCs. (B) Correlation between TILDA and the *Alu*-PCR assay for HIV DNA in PBMCs. (C) Correlation between TILDA and the droplet digital PCR assay for HIV DNA in rectal CD4 + T cells. (D) Correlation between TILDA and the droplet digital PCR assay for HIV DNA in resting CD4 + T cells. (E) Correlation between TILDA and the *Alu*-PCR assay for HIV DNA in resting CD4 + T cells. (F) Correlation between TILDA and single copy assay for residual viremia. (G) Correlation between TILDA and Q-VOA in resting CD4 + T cells. Black circles and grey circles denote subjects who started ART during chronic and early infection, respectively. P values were obtained from the Pearson (A, B, C, E, G) or Spearman test (D, F), according to the results of the normality test (see [Methods](#s0010){ref-type="sec"}).](gr2){#f0010}

![Initiation of ART during early HIV infection leads to a restricted size of the reservoir measured by TILDA. The frequency of cells harbouring inducible msRNA was measured by TILDA on CD4 + T cells obtained from subjects who started ART during chronic (n = 17, red circles) or recent (n = 10, blue circles) infection. Horizontal bars indicate median values. P value was obtained from the Mann--Whitney test.](gr3){#f0015}

![TILDA reveals that untreated HIV-infected individuals harbour a large pool of latently infected CD4 + T cells. (A) Frequency of CD4 + T cells producing *tat*/*rev* msRNA spontaneously (baseline) or after 12 h of stimulation (induced) in 13 samples obtained from viremic, untreated HIV-infected individuals. Horizontal bars indicate median values. P value was obtained from the Wilcoxon matched-pairs signed rank test. (B) Correlation between the frequency of CD4 + T cells spontaneously producing HIV msRNA and HIV plasma viremia. P value was obtained from the Pearson test. (C) Proportion of CD4 + T cells that produce *tat*/*rev* msRNA spontaneously or after stimulation in untreated HIV-infected subjects. (D) Pie charts show the average relative proportions of productively and latently infected CD4 + T cells in virally suppressed (ART) and untreated viremic (VIR) HIV-infected subjects. P value was obtained from the Mann--Whitney test. (E) Correlation between the frequency of CD4 + T cells producing HIV msRNA after stimulation and duration of HIV infection. P value was obtained from the Pearson test. (F) Frequency of CD4 + T cells producing HIV msRNA before and after stimulation in the presence (+ ARVs) or absence (− ARVs) of antiretrovirals (raltegravir, efavirenz and AZT). P values were obtained from the Wilcoxon matched-pairs signed rank test.](gr4){#f0020}

###### 

Participant characteristics.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                  Sex[a](#tf0005){ref-type="table-fn"}   CD4 count (cells/μl)   CD8 count (cells/μl)   HIV viral load (copies/ml)   Duration of HIV infection (years)[b](#tf0010){ref-type="table-fn"}   Duration of ART (years)[c](#tf0015){ref-type="table-fn"}   ART regimen[d](#tf0020){ref-type="table-fn"}
  ------------------------------- -------------------------------------- ---------------------- ---------------------- ---------------------------- -------------------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------
  *Virally suppressed subjects*                                                                                                                                                                                                                                                     

  ART1                            NA                                     1177                   935                    \< 20                        NA                                                                   6.5                                                        NA

  ART2                            M                                      1183                   912                    \< 20                        25.6                                                                 3.4                                                        ABC/3TC/ATV

  ART3                            M                                      1112                   594                    \< 20                        12.9                                                                 12.9                                                       ABC/3TC/NVP

  ART4                            M                                      326                    1085                   \< 20                        6.2                                                                  6.1                                                        TDF/FTC/EFV

  ART5                            M                                      612                    834                    \< 20                        25.7                                                                 16.9                                                       NA

  ART6                            M                                      1065                   1408                   \< 20                        15.0                                                                 8.2                                                        TDF/FTC/EFV

  ART7                            M                                      1145                   1410                   \< 20                        6.1                                                                  5.8                                                        TDF/FTC/LPV/r

  ART8                            M                                      1095                   736                    \< 20                        22.1                                                                 6.2                                                        TDF/FTC/EFV

  ART9                            M                                      876                    1389                   \< 20                        5.7                                                                  5.0                                                        ABC/3TC/EFV

  ART10                           F                                      522                    238                    \< 20                        22.1                                                                 7.5                                                        TDF/FTC/ATV/r

  ART11                           F                                      460                    1879                   \< 20                        5.4                                                                  4.4                                                        TDF/FTC/RAL/LPV/r

  ART12                           F                                      355                    815                    \< 20                        21.1                                                                 4.7                                                        TDF/FTC/DRV/r

  ART13                           M                                      289                    512                    \< 20                        16.2                                                                 3.0                                                        TDF/FTC/LPV/r

  ART14                           F                                      351                    344                    \< 20                        15.1                                                                 3.6                                                        TDF/FTC/ATV/r

  ART15                           M                                      734                    703                    \< 20                        7.2                                                                  2.5                                                        TDF/FTC/RAL

  ART16                           M                                      267                    518                    \< 20                        NA                                                                   3.8                                                        TDF/FTC/EFV

  ART17                           M                                      1102                   875                    \< 20                        NA                                                                   NA                                                         TDF/FTC/ATV

  ART18                           M                                      291                    491                    \< 20                        10.4                                                                 2.9                                                        ABC/3TC/ATV/r

  ART19                           M                                      1897                   830                    \< 20                        NA                                                                   6.1                                                        TDF/FTC/EFV

  ART20                           M                                      387                    625                    \< 20                        NA                                                                   6.3                                                        ABC/3TC/ATV

  Median\                                                                734 \[353--1107\]      815 \[556--1010\]      \< 20 \[\< 20-- \< 20\]      15 \[6.7--21.6\]                                                     5.8 \[3.7--6.4\]                                           
  \[IQR\]                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                    

  *Viremic subjects*                                                                                                                                                                                                                                                                

  VIR1                            F                                      319                    470                    51,000                       11.8                                                                 --                                                         --

  VIR2                            M                                      434                    2497                   51,000                       2.5                                                                  --                                                         --

  VIR3                            F                                      548                    751                    23,000                       18.0                                                                 --                                                         --

  VIR4                            M                                      480                    1552                   3300                         5.7                                                                  --                                                         --

  VIR5                            M                                      258                    1704                   400,000                      5.1                                                                  --                                                         --

  VIR6                            M                                      185                    647                    50,000                       9.0                                                                  --                                                         --

  VIR7                            F                                      284                    605                    21,000                       5.1                                                                  --                                                         --

  VIR8                            F                                      681                    543                    15,000                       8.0                                                                  --                                                         --

  VIR9                            M                                      499                    1590                   52,915                       9.9                                                                  --                                                         --

  VIR10                           NA                                     543                    896                    6077                         4.0                                                                  --                                                         --

  VIR11                           M                                      732                    1506                   51,647                       0.4                                                                  --                                                         --

  VIR12                           M                                      506                    948                    2959                         1.1                                                                  --                                                         --

  VIR13                           M                                      1400                   2040                   8082                         0.4                                                                  --                                                         --

  Median\                                                                499 \[319--548\]       948 \[647--1590\]      23,000 \[8082--51,000\]      5.1 \[2.5--9.0\]                                                                                                                
  \[IQR\]                                                                                                                                                                                                                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: not available.

Duration of HIV infection was calculated from the date of diagnosis of HIV infection.

Time of documented suppression of viremia to \< 50 copies/ml on ART.

Drug abbreviation: 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; ATV/r, atazanavir boosted with ritonavir; DRV/r, darunavir boosted with ritonavir; EFV, efavirenz; FTC, emtricitabine; LPV/r, lopinavir boosted with ritonavir; NVP, nevirapine; RAL, raltegravir; TDF, tenofovir disoproxil fumarate.

###### 

Results from the virological assays used in this study.

                                                      Q-VOA                               TILDA                                      Tot. HIV DNA in PBMCs   Tot. HIV DNA in CD4     Int. HIV DNA in PBMCs   Int. HIV DNA in CD4     Tot. HIV DNA in GALT cells             Residual viremia plasma
  --------------------------------------------------- ----------------------------------- ------------------------------------------ ----------------------- ----------------------- ----------------------- ----------------------- -------------------------------------- -------------------------
  Method[a](#tf0025){ref-type="table-fn"}             Cell culture in limiting dilution   Stimulation and PCR in limiting dilution   ddPCR                   ddPCR                   *alu*-PCR               *alu*-PCR               ddPCR                                  SCA
  Sample                                              Resting CD4 + T cells               Total CD4 + T cells                        PBMCs                   Resting CD4 + T cells   PBMCs                   Resting CD4 + T cells   GALT CD4 + T cells                     Plasma
  Unit                                                Infectious unit/10^6^ cells         Cells expressing msRNA/10^6^ cells         Copies/10^6^ cells      Copies/10^6^ cells      Copies/10^6^ cells      Copies/10^6^ cells      Copies/10^6^ cells                     Copies/ml
  n samples                                           27                                  27                                         27                      14                      18                      15                      17                                     27
  Median                                              0.5                                 23.8                                       150                     307.5                   234.5                   767                     5301                                   0.5
  Ratio with TILDA[b](#tf0030){ref-type="table-fn"}   0.021                               --                                         6.3                     13.4                    9.0                     27.1                    226[c](#tf0035){ref-type="table-fn"}   NA
  Max. value                                          16                                  100.6                                      1858                    1200                    1248                    2997                    13,388                                 2.2
  Min. value                                          0.0315                              1.4                                        1                       1                       19                      108                     259                                    0.1

ddPCR: droplet digital PCR; SCA: single copy assay. NA: not applicable.

Median values were used to calculate the ratio. Samples for which one of the 2 measurements used in each comparison was not performed were excluded.

Ratio between GALT DNA and TILDA measured in blood.
